How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 23 April 2015 12:38

There's a new kind of incubator in town. The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian nonprofit that fosters hands-on association between academia, government, industry and where to get viagra cheap investors to grow stem cell and canadian pharmacy discount code viagra regenerative medicine companies from the cialis once daily ground up. In this interview with The Life Sciences Report, 

Read more...
 

How to Profit from Australia's Healthiest Biotechs: Wilson HTM's Shane Storey

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 16 April 2015 12:51

Australia will always be known as a trove of natural resources, but its most precious treasure is the canadian generic cialis abundance of entrepreneurs who are all too happy to develop the viagra vs cialis vs levitra which is better country's intellectual assets.

Read more...
 

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 09 April 2015 19:21

It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised patience.

Read more...
 

Why Biotech Investors Should Target the Takeouts: Cantor Fitzgerald's Irina Rivkind Koffler

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 02 April 2015 14:39
Taking a page out of Big Pharma's playbook—looking for likely takeout candidates—is a profitable way to approach small-cap biotechs as potential investments, especially since large caps with shrinking pipelines have an unquenchable hunger for good new drugs and brand cialis for sale technologies, and the resources to track those drugs and technologies down.
Read more...
 

Five Stocks Griffin Securities' Keith Markey Thinks Could Double or Triple

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 12 March 2015 12:50

For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and best price zithromax efficacy, there's just no betting on a biotech stock.

Read more...
 

How to Beat the Herd Mentality: Highline's Michael Higgins

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 26 February 2015 15:04
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island.
Read more...
 

Immuno-Oncology Promises Continued Wealth and indian cialis generic Health: LifeTech Capital's Stephen Dunn

Print E-mail
By Staff - The Life Sciences Report   
Thursday, 19 February 2015 15:38

Immuno-oncology disabling cancer's defenses so that a patient's own immune system can seek it out and buy now viagra destroy it took center stage in the drug development world in 2014.

Read more...
 

Bloom Burton's David Martin Zeroes In on Under-the-Radar Biotech

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 12 February 2015 16:26

Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and buy nexium online biotech companies based in Canada, where resource stocks have absorbed so much investment capital that many healthcare names have remained hidden and female viagra 2012 undervalued.

Read more...
 

Capture Growth with Baskets of Biotechs: LifeSci Advisors' Andrew McDonald

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 05 February 2015 19:01
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development.
Read more...
 

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here?

Print E-mail
By Tracy Salcedo-Chourré of The Life Sciences Report   
Thursday, 29 January 2015 18:14
At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and buy orlistat found every reason to believe its good health would continue into 2015 and beyond.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 50

Newsletter

BioMedReports Ardelyx Reports Results from Phase 2a Clincial Trial Evaluating Tenapanor; ZIOPHARM Announces Initiation of Ph... http://t.co/Y3kDts8Sn1
3hreplyretweetfavorite
BioMedReports New Fixes for Worn Knees http://t.co/4oJyMSf6CK
4hreplyretweetfavorite
BioMedReports CytRx Corporation (NASDAQ:CYTR) Soars 19% On ongoing phase 1b aldoxorubicin combination studies: Biopharmaceut... http://t.co/HtNmO2QxN2
20hreplyretweetfavorite